Agilent gene expression microarray raw data for STO-3
Citation and access
Citation and access
Data access level:
Creator/Principal investigator(s):
Research principal:
Data contains personal data:
Yes
Type of personal data:
Pseudonymised data
Code key exists:
Yes
Sensitive personal data:
Yes
Citation:
Language:
Method and outcome
Method and outcome
Population:
Breast cancer patients diagnosed in Stockholm 1976-1990
Study design:
- Randomised controlled trial (RCT)
- Experimental study
Variables:
31195
Number of individuals/objects:
652
Data format/data structure:
Samples/material - Existing from scientific collection/biobank
Samples/material - Existing from scientific collection/biobank
Name:
Type(s) of sample:
Data collection - Registry extract and/or access to biobank sample
Data collection - Registry extract and/or access to biobank sample
Mode of collection:
Registry extract and/or access to biobank sample
Time period(s) for data collection:
2013 - 2014
Source of the data:
- Biological samples
Geographic coverage
Geographic coverage
Geographic location:
Administrative information
Administrative information
Responsible department/unit:
Department of Oncology-Pathology [K7]
Ethics Review:
Stockholm - 2017/2066-32, 97-451, 76-51.
The STO-3 trial was approved by the ethics committee at Karolinska Institutet and participants provided oral consent. The trial was conducted at the Regional Cancer Center Stockholm-Gotland, Sweden, and began in 1976
Funding
Funding
Funding agency:
- Swedish Research Council
Opens a new window at ror.org.
ROROpens in a new tab
Award number:
2014-02057_VR
Award title:
Intra-tumor heterogeneity: A marker of breast cancer tumor aggressiveness influencing long-term patient survival?
Funding information:
Breast cancer is the most common cancer and cause of death in women. The clinically used markers to characterize breast cancer tumors include hormonal receptors, the HER2 growth factor and tumor proliferation. However, it is not possible to accurately predict a woman´s long-term survival from these breast cancer markers and one out of five women diagnosed with early-stage breast cancer will later develop distant metastatic disease and die from her disease. We and others have shown that the clinically used breast cancer markers alter throughout tumor progression, which significantly influences patient survival. What are the likely explanations to our findings? It has been suggested that tumors possess intra-tumor heterogeneity of tumor characteristics with varying aggressiveness, for instance hormonal sensitive and hormonal insensitive tumor cells within the same tumor. Our aim is therefore to determine if intra-tumor heterogeneity increase the risk of fatal breast cancer disease. We will assess intra-tumor heterogeneity of tumor characteristics and identify genes that are heterogeneous within tumors by single-cell sequencing. Discovery of new predictors for fatal breast cancer disease has the potential to be vital for patient management. In the clinical setting this distinction is essential since accurate risk prediction allows for individualized therapy, supporting aggressive adjuvant therapy for high-risk patients, potentially prolonging survival and saving patient lives.
Funding agency:
- Swedish Research Council
Opens a new window at ror.org.
ROROpens in a new tab
Award number:
2020-02466_VR
Award title:
The prognostic and therapeutic impact of intra-tumor heterogeneity in estrogen receptor-positive breast cancer
Funding information:
Approximately 50% of patients with estrogen receptor (ER)-positive breast cancer do not benefit from anti-hormonal (endocrine) treatment, and around one out of four will die from the disease, some decades after primary diagnosis. It is currently not possible to accurately predict the long-term risk for fatal disease, and the biological factors influencing this risk are not well understood. Our goal is to improve the prediction of patients’ risk for fatal breast cancer. Tumors with marked intra-tumor heterogeneity may shed tumor cells with different characteristics some of which may enable tumor cell invasion and survival at a distant site. We will determine the influence of intra-tumor heterogeneity on the risk of fatal breast cancer and on the benefit of endocrine treatment. Intra-tumor heterogeneity of the clinically used tumor characteristics as well as other tumor characteristics will be evaluated. We will use unique and large clinical trials performed in Stockholm with patients randomized to endocrine therapy versus not and a follow-up of at least 20 years. To establish heterogeneity we will use pathologist scored immunohistochemistry, an automated image analysis tool that we are developing, and inter-cell heterogeneity of genes expressed within the same tumor. The distinction of risk is essential, since accurate risk prediction allows for individualized treatment, decreases anxiety, and supports aggressive adjuvant treatment for patients with high-risk of fatal disease.
